Completed Enrollment

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)

I8F-MC-GPHJ -

The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide 2.4 milligram (mg) in adult participants who have obesity or overweight with weight related comorbidities without type 2 diabetes.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Overweight, Obesity
What the trial is testing?
Tirzepatide, Semaglutide
Could I receive a Placebo?
No
Enrollment Goal
700
Trial Dates
Apr 21, 2023 - Nov 2024
How long will I be in the trial?
The study will last about 78 weeks and may include up to 21 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have obesity

  • Have overweight with at least one:

    • obstructive sleep apnea

    • Have high blood pressure

    • Have high cholesterol

    • Have heart disease

Participants Must Not:

  • Have type 1 or type 2 diabetes

  • Have a self-reported change in body weight over 5 kg within 3 months before screening

  • Have a planned or prior surgery for obesity

  • Have “severe” kidney impairment

  • Have long-term or short- term inflammation of the pancreas

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources